RESEARCH

AlivaMab Discovery Services is Expanding the Drug Discovery Platform with the Introduction of New Antibody Engineering Department

AlivaMab | May 13, 2021

AlivaMab Discovery Services, LLC ("ADS"), a pioneer in the discovery of superior antibody therapeutics, announced today the formation of its new Antibody Engineering Department, headed by Jonah Rainey, Ph.D. Jonah joins ADS as Vice President of Antibody Engineering, bringing 15 years of experience from Macrogenics Inc. in antibody engineering, discovery, and development, MedImmune, LLC/AstraZeneca PLC, Gritstone Bio, Inc., and, most recently, Immetas Therapeutics, Inc. Jonah's expertise in antibody engineering includes bispecific antibodies, some of which have reached clinical trials, antibody-drug conjugates, Fc modification, in vitro display for antibody discovery and optimization, and structural modeling.

“An increasing number of leading pharma and biotechs realize that ADS's pre-existing platform process adds exceptional value to their antibody drug discovery efforts. I am excited to be leading the initiative at ADS to develop new capabilities that will expand the scope and importance that we offer to our clients' drug discovery and development projects. The new Antibody Engineering Department's commitment will help to ensure that ADS delivers the best antibody drug candidates,” said Jonah Rainey, Vice President of Antibody Engineering at AlivaMab Discovery Services.

“Today, we significantly expand the ADS discovery platform by adding a new pillar of antibody engineering to our existing pillars of Ablexis' AlivaMab® Mouse, the leading transgenic animal technology for antibody drug discovery, a suite of AMMPD immunization technologies to address even the most challenging targets, a broad sampling of the immune repertoire through function-first high-throughput deep sequencing, and a broad sampling of the immune repertoire through function-first high-throughput sequence analysis. “Jonah's skills and abilities complement and reinforce the ADS team's accumulated decades of experience in discovery and development. We assist our clients in delivering quality medicines to patients quicker by combining team, technology, and partnership.”

About AlivaMab Discovery Services
AlivaMab Discovery Services is a privately-owned biotechnology company that develops an integrated antibody therapeutic discovery platform that combines innovative technologies and deep expertise to produce superior antibody therapeutics on time. Throughout their careers, the team has completed over 200 discovery projects, yielding several antibody drug candidates in clinical trials. ADS offers a wide range of antibody therapeutic candidates with complex molecular and epitope profiles, functional and kinetic characterization, and superior developability profiles.ADS is trusted by organizations ranging from global pharmaceutical firms to virtual biotechnology companies because of its business model that relies solely on partners instead of developing an internal product pipeline.

Spotlight

Cell and gene therapies (CGTs) are continuing to gain momentum in life sciences globally. However, Asia Pacific (APAC) has demonstrated the most growth in CGT
developers of any other region, with a rise of 10% in
H1 2022 compared to 2021.1

Spotlight

Cell and gene therapies (CGTs) are continuing to gain momentum in life sciences globally. However, Asia Pacific (APAC) has demonstrated the most growth in CGT
developers of any other region, with a rise of 10% in
H1 2022 compared to 2021.1

Related News

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Enlaza Therapeutics Launches with $61 Million Financing to Advance the First Covalent Biologic Therapeutic Platform

Enlaza Therapeutics | December 19, 2022

Enlaza Therapeutics, the first covalent biologic platform company, announced its official launch with the closing of $61 million in seed financing. The financing was led by Avalon Ventures and joined by Lightspeed Venture Partners, Frazier Life Sciences, and Samsara BioCapital. The financing will be used to further advance Enlaza’s proprietary War-LockTM platform and build a pipeline of covalent biologics with an initial focus on developing novel, differentiated cancer therapeutics with targeted efficacy and low toxicity. “We’ve combined recent breakthroughs that allow introduction of proprietary unnatural amino acids to protein drugs, which enables specific covalent binding to their target proteins. Our covalent biologic platform is white-space technology, and we are pioneering an entirely new class of biologic therapeutics with the potential for significantly improved efficacy and safety to address numerous indications and disease areas.” Sergio Duron, Ph.D., CEO of Enlaza Therapeutics “Enlaza has built a highly differentiated therapeutic platform which, for the first time, will enable covalent biologics,” said Jay Lichter, Ph.D., Managing Partner of Avalon Ventures. “The platform provides the opportunity to develop drugs against multiple target classes, offering opportunities across all therapeutic areas.” The War-Lock platform creates highly specific therapeutic warheads that lock onto targets of interest, producing broadly applicable therapeutic candidates with excellent drug-like properties. For example, protein drugs derived from the platform can be modified to incorporate various payloads, creating antibody-drug conjugates (ADCs) or radioligand therapies (RLTs) with specific target tissue delivery, without the need for half-life extension engineering. Enlaza has generated preclinical data for its oncology drug candidates showing fast tumor penetration coupled with high systemic clearance, high tumor retention, and low off-target toxicity. “The breadth of Enlaza’s platform will be transformative across multiple modalities,” said Shelley Chu, M.D., Ph.D., Partner at Lightspeed Venture Partners. Marcos Milla, Ph.D., Venture Partner at Samsara BioCapital said, “The Enlaza platform opens the possibility to enhance the therapeutic index of biologic drugs in a way that is not accessible with platforms relying on conventional recombinant technologies. It also offers an opportunity to address hard to target cell surface molecules in a highly specific fashion.” “We are impressed with the in vitro and in vivo data the team has generated and believe that Enlaza can build an industry leading pipeline of important new protein drugs employing its incomparable technological advantage,” said Jamie Topper, M.D., Ph.D., Managing Partner of Frazier Life Sciences. Enlaza’s War-Lock platform is based on technologies exclusively licensed from UCSF, negotiated through UCSF’s Innovation Ventures’ Office of Technology Management & Advancement, which leads licensing and business development efforts on behalf of the University, and The Scripps Research Institute. About Enlaza Therapeutics Enlaza Therapeutics is pioneering the field of covalent biologics. These novel classes of protein therapeutics deliver more efficacious and safer treatments for patients. The company's proprietary War-LockTM platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza is building a pipeline of first-in-class covalent biologics.

Read More

INDUSTRIAL IMPACT

Alloy Therapeutics and Normunity Sign Multi-Program Antibody Discovery Collaboration in Immuno-Oncology

Alloy Therapeutics | November 18, 2022

Alloy Therapeutics, a biotechnology ecosystem company, announced an antibody discovery collaboration spanning multiple precision immuno-oncology programs for Normunity, a biotech company that recently announced its $65 million Series A financing. The collaboration will support the advancement of Normunity’s immune normalizers, antibody therapies designed to target novel mechanisms that free the body’s normal immunity to fight cancer, which are conceived through a unique biotech-academic collaboration with a renowned immuno-oncology university research lab. Alloy democratizes access to tools, technologies, and services that are foundational for discovering and developing therapeutic biologics and has partnered with more than 130 discovery teams across academia, biotech, and large biopharma organizations. Through its discovery services offering, Alloy conducts high-touch, bespoke therapeutic discovery campaigns against partners’ targets of interest. “Our partnership reflects an exciting opportunity to pair Normunity’s insights in immune disruption and cancer disease biology with Alloy’s world-class antibody discovery expertise. We value Alloy’s collaborative approach and look forward to working together to advance the best therapeutic antibodies to target mechanisms discovered through Normunity’s platforms.” Normunity Chief Scientific Officer William LaRochelle, PhD The collaboration between Alloy and Normunity is leveraging Alloy’s high velocity antibody discovery services offering, Daedamab, which takes a sequencing-first approach to antibody discovery that reduces discovery timelines without sacrificing quality. The Daedamab team is based in Alloy’s research facility in Athens, GA, and its workflow comprises the ATX-Gx™, Alloy’s proprietary mice platform for human therapeutic antibody discovery, in addition to robust B cell isolation, next generation sequencing, cloning-free expression and a high throughput screening process—all supported by a rich informatics engine. “We are very excited to work with Normunity on its set of unique immuno-oncology targets using our high velocity NGS-based antibody discovery methods leveraging the ATX-Gx platform," said Richard Shimkets, PhD, SVP of Genetics and New Technologies at Alloy Therapeutics and CEO of the Daedamab site. “This relationship is emblematic of Alloy’s expertise in deploying the right technologies and processes to find our partners the best therapeutic antibodies against the novel targets they bring us.” Normunity is advancing into the clinic with programs that target mechanisms that drive the exclusion of T cells into immune-sensitive tumors and aim to deliver an active and effective immune system into cold tumors. About Daedamab Alloy’s Daedamab discovery service offers a novel, fast, powerful sequence-first approach to finding and making the best antibodies. The team is based in Athens, GA and supports Alloy collaborators with complete antibody discovery services, antibody sequencing of customer-provided material, expression and testing of customer-provided antibody sequences, humanization, and optimization services. About Alloy Therapeutics Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners across academia, biotech, and the largest biopharma, Alloy democratizes access to pre-competitive tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics across six modalities, including antibodies, TCRs, genetic medicines, peptides, cell therapies, and drug delivery. Partners may access all current and future technologies for a flat annual fee through Alloy’s Innovation Subscriptions offering. As a reflection of Alloy’s relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation. About Normunity Normunity, Inc., is a biotechnology company creating a new class of precision immuno-oncology medicines, called immune normalizers, that target novel mechanisms that free the body’s normal immunity against cancer. Based on an ongoing, interactive academic-biotech partnership with the lab of Dr. Lieping Chen at Yale School of Medicine, Normunity is targeting newly-discovered mechanisms of immune disruption in cancer based on proprietary discovery platforms that elucidate the complex interactions between human cancer and the immune system. The company is advancing an emerging pipeline of immune normalizers, including initial drug programs that target mechanisms that drive the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function in cancer. Normunity is located in Boston, Mass. and West Haven, Conn.

Read More

CELL AND GENE THERAPY, MEDICAL

Be The Match BioTherapies® Introduces CIBMTR® CRO Services

Be The Match BioTherapies® | January 18, 2023

On January 17, 2023, Be The Match BioTherapies, a company that provides solutions for organizations that develop and commercialize cell and gene therapies, introduced its offering of CIBMTR® clinical research organization services (CRO services), which significantly reduces the time needed to launch and execute high-impact clinical trials. These CRO services are the outcome of a collaboration between Be The Match BioTherapies and CIBMTR, resulting in expertise and access to unmatched research, sites, donors, partnerships, scientific and operational knowledge, and other resources. CIBMTR CRO services offer unique capabilities such as Established relationships with over 225 clinical locations domestically Nearly 20 years of expertise in transplant and cellular therapy trials and study management, as well as clinically-trained staff On-staff transplant physicians provide direct contact with patients and donors for clinical and research insights. A link to the CIBMTR outcomes database for over 575,000 patients The new CRO services offer turn-key solutions, including protocol development and approval oversight, site selection, project management, site start-up, research sample/laboratory coordination, data management, study monitoring, patient-reported outcomes, statistical analysis, and financial administration. For certain services, such as data analysis, surveys, site selection and administration, and sample management, businesses may instead rely on the expertise of CIBMTR CRO services. About Be The Match BioTherapies® Be The Match BioTherapies is the sole supplier of cell and gene therapy solutions with fully configurable services to assist the cell therapy supply chain. It is committed to accelerating patient access to life-saving cell and gene treatments by delivering the best-quality cellular source material from Be The Match Registry®, the most-varied registry of prospective blood stem cell donors in the world, with over 7 million potential blood stem cell donors. Through global collaborations with apheresis, bone marrow collection, and transplant centers, the firm creates, onboards, trains, and maintains extensive collection networks to advance cell treatments.

Read More